Regulation of transforming growth factor-β1 gene expression and cell proliferation in human hepatocellular carcinoma cells (PLC/PRF/5) by tamoxifen

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 1, 1999, Pages 90-95

  Gong, Yuewen ^a   Zhang, Manna ^b   Minuk, Gerald Y ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033166480     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90058-6     Document Type: Article

References (27)

1. 1. Sherman M. Hepatocellular carcinoma. Gastroenterology 1995;3:55-66.
2. 2. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991;36:962-72.
3. 3. Wanless IR, Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest 1982;46:313-20.
4. 4. Farinati F. Tamoxifen treatment in hepatocellular carcinoma [letter; comment]. Gastroenterology 1996;111:272-4.
5. 5. Engstrom PF, Levin B, Moertel CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990;65:2641-3.
6. 6. Farinati F, Salvagnini M, de Maria N, Fomasicro A, Chiaramonte M, Rossaro L, et al. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990;11:297-301.
7. 7. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. 1995;109:917-22.
8. 8. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995;21:1535-42.
9. 9. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer 1993;29A:1152-7.
10. 10. Kim JH, Chung JB, Park IS, Kim BS, Yoo NC, Choi JH, et al. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. Yonsei Med J 1993;34:35-44.
11. 11. Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD, et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998;55:523-31.
12. 12. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, et al. Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992;83:676-9.
13. 13. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, et al. Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995;89:45-8.
14. 14. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 1995;136:2172-8.
15. 15. Harrington CR. Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue. Anal Biochem 1990;186:285-7.
16. 16. Kropf J, Schurck JO, Wollner A, Gressner AM. Immunological measurement of transforming growth factor-beta 1 (TGF-beta 1 ) in blood; assay development and comparison. Clin Chem 1997;43:1965-74.
17. 17. Sladowski D, Steer SJ, Clothier RH, Balls M. An improved MTT assay. J Immunol Methods 1993;157:203-7.
18. 18. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang W, et al. Elevated urinary transforming growth factor-beta 1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997;76:244-50.
19. 19. Ito N, Kawata S, Tamura S, Takaishi K, Yabuuchi I, Matsuda Y, et al. Expression of transforming growth factor-beta 1 mRNA in human hepatocellular carcinoma. Jpn J Cancer Res 1990;81:1202-5.
20. 20. MacCallum J, Keen JC, Bartlett JM, Thompson AM, Dixon, JM, Miller WR. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy [comment]. Br J Cancer 1996;74:474-8.
21. 21. Heel RC, Brogden RN, Speight TM, Avery GS. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 1978;16:1-24.
22. 22. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.
23. 23. El-Tanani MK, Green CD. Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol 1997;11:928-37.
24. 24. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifcn activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of anti-estrogens. Mol Endocrinol 1995;9:443-56.
25. 25. Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996;56:3883-5.
26. 26. Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995;55:498-500.
27. 27. Villa E, Dugani A, Moles A, Camellini L, Grottola A, Buttafoco P, et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 1998;27:983-8.